SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

HAMBURG, GERMANY / ACCESS CABLE / August 4, 2022 / Evotec SE (Frankfurt Values Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half of 2022 on Thursday, August 11, 2022.

The Company will hold a conference call to discuss the results and provide an update on its performance. The conference call will be held in English.

Conference call details

Date: Thursday, August 11, 2022
Weather: 14:00 CEST (08:00 EDT, 13:00 BST)

From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From the UK: +44 20 3009 2470
From the US: +1 877 423 0830
Access code: 37893553#

A simultaneous slide show for participants dialing in by phone is available at

Webcast details

To join the audio webcast and access the presentation slides, you will find a link on our home page shortly before the event.

The on-demand version of the webcast will be available on our website:


Evotec is a life sciences company with a unique business model that fulfills its mission to discover and develop highly effective therapies and make them available to patients. The company’s multimodal platform comprises a unique combination of innovative technologies, data and science for the discovery, development and production of world-class and best-in-class pharmaceuticals. Evotec leverages this “Data Driven R&D Autobahn to Cures” for proprietary projects and within a partner network that includes the top 20 pharmaceutical and over 800 biotech companies, academic institutions and other health care stakeholders. health. Evotec has strategic activities in a wide range of currently underserved therapeutic areas, including, for example, neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world’s leading co-owned product portfolio for innovative therapies, and to date has established a portfolio of over 200 co-owned and co-owned R&D projects, from initial discovery through clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company’s 16 sites offer highly synergistic technologies and services and operate as complementary groups of excellence. For additional information, go to and follow us on Twitter @Evotec Y LinkedIn.


This announcement contains forward-looking statements about future events, including the proposal offering and list of values ​​of Evotec. Words like “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “potential”, “should”, “target”, ” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments on Evotec’s expectations regarding revenues, Group EBITDA and non-associated R&D expenses. These forward-looking statements are based on available information and expectations and assumptions that Evotec believed to be reasonable at the time these statements were made. There can be no guarantee that such expectations will turn out to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly disclose any update or revision of the forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances in which any statement is based.

Evotec SE IR contact:
Volker Braun, Senior Vice President Global Investor Relations and ESG, Phone: +49.(0)40.56081-775, [email protected]

FONT: Evotec SE

See source version at access

Source link

Leave a Reply

Your email address will not be published.